SuperworthOcugen OCGN
- Market cap
- $250.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −24.3%
Ocugen's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.7M+694% | $1.4M+60% | $1M+129% | $1.1M+135% | $1.1M−69% | $764K−46% | $1.5M+46% | $1.4M+20% | $1.8M+54% | n/a | $1.5M+4% | $1.5M+8% | |
| R&D | $7M−55% | $7.8M−55% | $6.8M−33% | $8.9M−39% | $8.1M+15% | $8.3M+7% | $9.5M+40% | $8.4M−6% | $11.1M+38% | n/a | $11.3M+18% | $10.7M+27% |
| SG&A | $9.1M+21% | $5.2M−26% | $6.4M−23% | $7.7M−19% | $6.3M−31% | $6.3M+23% | $6.5M+1% | $6.8M−12% | $8.2M+31% | n/a | $8.1M+26% | $7.2M+7% |
| −$12.4M−46% | −$11.5M−52% | −$12.2M−32% | −$15.4M−34% | −$13.3M+7% | −$13.8M+20% | −$14.5M+19% | −$13.8M−11% | −$17.6M+33% | n/a | −$17.8M+23% | −$16.4M+19% | |
| Interest expense | n/a | n/a | n/a | n/a | $29K | n/a | $1.3M | $1.3M | $1.3M+4431% | n/a | $1.3M+5% | $4.5M+248% |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$11.7M−47% | −$11M−50% | −$11.9M−31% | −$15.3M−34% | −$13M+11% | −$13.9M+27% | −$15.3M+29% | −$14.7M−4% | −$20.1M+55% | −$17.7M+28% | −$19.2M+25% | −$24.9M+69% |
| −$0.05−50% | −$0.04−60% | −$0.05−38% | −$0.06−40% | −$0.05+0% | −$0.05+25% | −$0.05+0% | −$0.05−17% | −$0.07+40% | −$0.06+20% | −$0.06+20% | −$0.07+40% | |
| 256.5M+18% | 256.5M+17% | 257.2M+14% | 257.4M+8% | 278.2M+9% | 290.9M+13% | 292M+14% | 292.1M+14% | 304M+9% | 312.3M+7% | 327.5M+12% | 338.7M+16% |
EPS, diluted: 12 periods, Q4 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY14 and Q4 FY19: share-days: the 12-month average less the 9-month, weighted by days. 9 periods, Q4 FY15 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY16: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Ocugen's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| OCGNOcugen | $250.8M | n/m | n/a | n/m | n/m | n/m | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| MGTXMeiraGTx | $884.6M | 13.0× | 18.0× | 2.2× | n/m | 19.9% | |
| VCELVericel | $2.2B | 92.5× | 158× | 7.1× | +23% | 7.9% | |
| ADMAAdma Biologics | $2.4B | 15.3× | 21.5× | 4.7× | +8% | 33.0% | |
| Peer median | $1.5B | 14.1× | 27.8× | 3.6× | +23% | 21.7% |
More on Ocugen
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .